142 related articles for article (PubMed ID: 20968021)
21. [Primary treatment of early stage Hodgkin's disease].
Molnár Z; Esik O; Illés A
Orv Hetil; 2005 Jan; 146(2):57-61. PubMed ID: 15724953
[TBL] [Abstract][Full Text] [Related]
22. Treatment of Stage IIIa Hodgkin's disease: long follow-up perspective.
Lister TA
J Clin Oncol; 2008 Nov; 26(32):5144-6. PubMed ID: 18854554
[No Abstract] [Full Text] [Related]
23. Prospective study of combined modality treatment or radiotherapy alone in the management of early-stage adult Hodgkin's disease.
Yildiz F; Zengin N; Engin H; Güllü I; Barista I; Caglar M; Ozyar E; Cengiz M; Gürkaynak M; Zorlu F; Caner B; Atahan IL; Tekuzman G
Int J Radiat Oncol Biol Phys; 2004 Nov; 60(3):839-46. PubMed ID: 15465201
[TBL] [Abstract][Full Text] [Related]
24. [Evaluation of the effectiveness of chemoradiotherapy of stage IIIA Hodgkin's disease].
Kanaev SV; Gershanovich ML; Malinin AP; Kholin AV
Med Radiol (Mosk); 1987 May; 32(5):16-21. PubMed ID: 3586917
[TBL] [Abstract][Full Text] [Related]
25. Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin's lymphoma: results of the HD8 trial of the German Hodgkin's Lymphoma Study Group.
Engert A; Schiller P; Josting A; Herrmann R; Koch P; Sieber M; Boissevain F; De Wit M; Mezger J; Duhmke E; Willich N; Muller RP; Schmidt BF; Renner H; Muller-Hermelink HK; Pfistner B; Wolf J; Hasenclever D; Loffler M; Diehl V;
J Clin Oncol; 2003 Oct; 21(19):3601-8. PubMed ID: 12913100
[TBL] [Abstract][Full Text] [Related]
26. Risk-adapted, combined-modality therapy with VAMP/COP and response-based, involved-field radiation for unfavorable pediatric Hodgkin's disease.
Hudson MM; Krasin M; Link MP; Donaldson SS; Billups C; Merchant TE; Kun L; Billet AL; Kaste S; Tarbell NJ; Howard S; Friedmann AM; Hurwitz CA; Young JA; Marcus KC; Rai S; Cowan T; Weinstein HJ
J Clin Oncol; 2004 Nov; 22(22):4541-50. PubMed ID: 15542805
[TBL] [Abstract][Full Text] [Related]
27. [High-dose chemotherapy and autologous stem cell transplantation for refractory and relapsing Hodgkin's disease as first-line therapy-- studies at Sheba Medical Center--Tel Hashomer].
Avigdor A; Hardan I; Shpilberg O; Raanani P; Grotto I; Ben-Bassat I
Harefuah; 2000 Sep; 139(5-6):174-9, 248, 247. PubMed ID: 11062945
[TBL] [Abstract][Full Text] [Related]
28. [Prognosis and treatment strategies of primary B-cell and NK/T-cell nasopharyngeal non-Hodgkin's lymphoma at early stage].
Zou GR; Zhang YJ; Xie FY; Zheng W; Li HX; Xia YF; Lin TY; Lu TX
Ai Zheng; 2006 Dec; 25(12):1543-9. PubMed ID: 17166383
[TBL] [Abstract][Full Text] [Related]
29. [Novel approaches to combination therapy of Hodgkin's disease].
Kharchenko VP; Pan'shin GA; Datsenko PV; Sotnikov VM; Mel'nik IuD
Vopr Onkol; 2005; 51(6):692-6. PubMed ID: 17037037
[TBL] [Abstract][Full Text] [Related]
30. Primary refractory Hodgkin's lymphoma: outcome after high-dose chemotherapy and autologous SCT and impact of various prognostic factors on overall and event-free survival. A single institution result of 66 patients.
Akhtar S; El Weshi A; Abdelsalam M; Hussaini H; Janabi I; Rahal M; Maghfoor I
Bone Marrow Transplant; 2007 Oct; 40(7):651-8. PubMed ID: 17660837
[TBL] [Abstract][Full Text] [Related]
31. [The role of radiotherapy in the treatment of Stage IIIA Hodgkin's disease in children].
Kanaev SV; Kolygin BA; Malinin AP; Chikrizov SI
Vopr Onkol; 1986; 32(9):53-6. PubMed ID: 3765524
[TBL] [Abstract][Full Text] [Related]
32. [Use of risk-adapted programs of treatment of Hodgkin's disease in children and adolescents].
Kuleva SA
Vopr Onkol; 2008; 54(6):768-70. PubMed ID: 19241857
[TBL] [Abstract][Full Text] [Related]
33. [Five-year outcome of a new combination chemotherapy with CEA/ABVD for advanced Hodgkin's disease with poor prognosis].
Kharchenko VP; Datsenko PV; Panyshin GA; Sotnikov VM; Mel'nik IuD
Vopr Onkol; 2006; 52(5):531-7. PubMed ID: 17168361
[TBL] [Abstract][Full Text] [Related]
34. Outcome of patients experiencing progression or relapse after primary treatment with two cycles of chemotherapy and radiotherapy for early-stage favorable Hodgkin's lymphoma.
Sieniawski M; Franklin J; Nogova L; Glossmann JP; Schober T; Nisters-Backes H; Diehl V; Josting A
J Clin Oncol; 2007 May; 25(15):2000-5. PubMed ID: 17420510
[TBL] [Abstract][Full Text] [Related]
35. Hodgkin's lymphoma in adolescents.
Foltz LM; Song KW; Connors JM
J Clin Oncol; 2006 Jun; 24(16):2520-6. PubMed ID: 16735704
[TBL] [Abstract][Full Text] [Related]
36. [Primary-refractory forms of Hodgkin's lymphoma].
Filatova LV; Tarasenkova AA; Gershanovich ML; Semiglazova TIu
Vopr Onkol; 2012; 58(5):627-38. PubMed ID: 23600279
[TBL] [Abstract][Full Text] [Related]
37. [The role of radiotherapy in the treatment for stage-IV Hodgkin lymphoma].
Kanaev SV; Girshovich MM
Vopr Onkol; 2015; 61(1):109-15. PubMed ID: 26016155
[TBL] [Abstract][Full Text] [Related]
38. Probability of cure in elderly Hodgkin's disease patients.
Levis A; Depaoli L; Urgesi A; Bertini M; Orsucci L; Vitolo U; Buchi G; Gallamini A; Gavarotti P; Novarino A; Rota Scalabrini D; Mazza U; Pileri A; Sannazzari GL; Resegotti L
Haematologica; 1994; 79(1):46-54. PubMed ID: 15378948
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of the prognostic meaning of C-reactive protein (CRP) in children and adolescents with classical Hodgkin's lymphoma (HL).
Haase R; Vilser C; Mauz-Körholz C; Hasenclever D; Kluge R; Ruschke K; Borkhardt A; Seeger K; Lehrnbecher T; Kulozik A; Rößler J; Burdach S; Jürgens H; Körholz D
Klin Padiatr; 2012 Oct; 224(6):377-81. PubMed ID: 23047832
[TBL] [Abstract][Full Text] [Related]
40. Hodgkin's lymphoma in younger patients: lessons learned on the road to success.
Hagemeister FB
Oncology (Williston Park); 2007 Apr; 21(4):434-40; discussion 441-2, 445-6. PubMed ID: 17474345
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
